SCHEMBL5535392

SCHEMBL5535392

c1ccc(-c2ccc(COC3CCNCC3)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.63
SLC6A4 P31645 4/20 0.63
SLC6A3 Q01959 4/20 0.63
HTR2A P28223 1/20 0.63
HTR2C P28335 1/20 0.63
HTR7 P34969 1/20 0.63
HTR2B P41595 1/20 0.63
HTR3A P46098 1/20 0.63
HTR4 Q13639 1/20 0.63
NAAA Q02083 5/20 0.54
CARM1 Q86X55 1/20 0.53
PRMT6 Q96LA8 1/20 0.53
KCNH2 Q12809 2/20 0.52
HRH1 P35367 4/20 0.50
F10 P00742 1/20 0.46
IDO1 P14902 2/20 0.46
AGXT P21549 2/20 0.46
HTR1A P08908 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902002 0.90 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
Hydrochloric Acid SCHEMBL1532893 0.88 SLC6A2 (0.64) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
SCHEMBL18615743 0.84 NAAA (0.58) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
SCHEMBL21493566 0.83 SLC6A2 (0.59) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
SCHEMBL5551135 0.83 NAAA (0.60) NAAACARM1PRMT6IDO1AGXT
Hydrochloric Acid SCHEMBL20268068 0.82 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
SCHEMBL14256259 0.81 CHRNB2 (0.59) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
SCHEMBL27691003 0.81 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
SCHEMBL18380998 0.79 SLC6A4 (0.58) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
SCHEMBL110365 0.79 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-102532162-A 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2012-07-04 CN disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SLC6A2 3396/4885SLC6A4 4191/4885SLC6A3 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.